Thoratec (NSDQ:THOR) started today up 7.2% as investors reacted to its stellar 1st-quarter numbers, but by the time the market closed THOR shares had fallen back to Earth to close at $34.46, down 0.1%.
The heart pump maker posted profits of $25.5 million, or 43¢ per diluted share, on sales of $126.8 million for the 3 months ended March 31.
Sign up to get our free newsletters delivered straight to your inbox
That amounts to bottom-line growth of 54.8% and top-line growth of 27.4%, compared with profits of $16.5 million, or 27¢ diluted EPS, on sales of $99.5 million during the same period last year.
Excluding 1-time items, adjusted EPS reached 51¢, a full dime above consensus estimates on The Street.
"I am encouraged by the ongoing success of our market development initiatives," president & CEO Gary Burbach said in prepared remarks. "In particular, we believe our first quarter results reflect continued progress in generating referrals of well-qualified candidates for HeartMate II therapy, as well as in facilitating program expansion across a broad group of centers, including the increasingly important open heart center segment."
Thoratec said it expects to log revenues of between $452 million and $467 million during 2012, with diluted EPS of $1.24-$1.34 and adjusted EPS of $1.62-$1.72. Analysts on The Street are predicting adjusted EPS of $1.65 this year.
Allergan’s Q1 sales rise, earnings soar
Allergan (NYSE:AGN) raised its Q1 top line by 9.5% and put an additional 45.2% on its bottom line.
The Irvine, Calif.-based company posted profits of $229.8 million, or 74¢ per share, on sales of $1.39 billion during the three months ended March 31.
That compares with profits of $158.3 million, or 51¢ per share, on sales of $1.27 billion during the same period last year. Read more
Endologix’s sales spike, losses soar
First-quarter sales for Endologix (NSDQ:ELGX) rose 59.6%, but losses widened by a whopping 239.1%.
The Irvine, Calif.-based firm posted losses of $16.3 million, or 28¢ per share, on sales of $24.5 million during the three months ended March 31.
That compares with losses of $4.8 million, or 9¢ per share, on sales of $15.4 million during the same period last year. Read more
Q1 profits plunge for Greatbatch
Greatbatch (NYSE:GB) saw its 1st-quarter profits slide some 62.6% despite a 6.9% addition to the top line.
The Clarence, N.Y.-based company posted profits of $4.5 million, or 19¢ per share, on sales of $159.1 million during the three months ended March 30.
That compares with profits of $11.9 million, or 51¢ per share, on sales of $148.8 million during the same period last year. Read more
Hospira’s Q1 sales slip, earnings slide
Hospira (NYSE:HSP) saw its Q1 sales slip 3.6% and earnings slide 73.2%.
The Lake Forest, Ill.-based company posted profits of $40.2 million, or 24¢ per share, on sales of $965.9 million during the three months ended March 31.
That compares with profits of $149.9 million, or 88¢ per share, on sales of $1.0 billion during the same period last year. Read more
ResMed’s Q3 sales, earnings up
ResMed (NYSE:RMD) boosted sales by 11.4% and profits by 21.1% during its fiscal 3rd quarter.
The San Diego-based firm posted profits of $64.6 million, or 44¢ per share, on sales of $349.1 million during the three months ended March 31.
That compares with profits of $53.4 million, or 34¢ per share, on sales of $313.3 million during the same period last year. Read more
